Certara to sell regulatory writing unit to Veristat for $135M

Certara agreed to sell its Regulatory and Medical Writing business to Veristat for up to $135 million, with closing expected in Q2 2026. The divested unit generated $50 million of revenue and $17 million of adjusted EBITDA in 2025, and Certara plans to update 2026 guidance after the transaction closes. The company also reported FY2025 revenue of $419 million, up 9% year over year, but the article highlights a 57% share decline over the past year and recent analyst downgrades.

Analysis

This is less a simple asset sale than a forced portfolio triage: Certara is monetizing a lower-growth, labor-heavy services asset to re-rate itself toward higher-multiple software and AI workflow revenue. The key second-order effect is margin mix, not headline proceeds — removing a business that likely dilutes gross margin stability should improve the market’s willingness to underwrite the core platform at a higher SaaS-like multiple, even if near-term reported revenue steps down.

The buyer profile matters. A strategic buyer can probably extract cross-sell and utilization gains from the writing group, which means the announced EBITDA multiple is likely understated versus private-market value to Certara but potentially attractive to Veristat if it can fill bench capacity. That also implies Certara may be exiting at the low point of a cyclical services margin trough, which is accretive to the turnaround story but creates a near-term earnings overhang because guidance reset risk usually lasts 1-2 quarters after closing.

The market may be underappreciating the signaling effect: management is effectively acknowledging that the conglomerate discount is real and that capital allocation will now be judged on focus, not scale. If execution improves, the stock could rerate off cleaner segment economics over 6-12 months; if bookings remain weak, the divestiture will be read as financial engineering rather than strategy and the multiple will stay compressed. For PWP, the transaction is immaterial economically but still mildly supportive of advisory-fee recognition and deal pipeline optics; BCS is not a direct beneficiary.

Key Decisions for Investors

• Initiate a tactical long CERT on confirmation of deal-close progress, targeting a 3-6 month window into guidance reset; upside comes from multiple expansion if investors accept a cleaner software/AI narrative, while downside is limited by the balance-sheet de-risking from proceeds.
• Use a pairs trade: long CERT / short a basket of lower-quality healthcare services names with similar labor intensity over the next 1-2 quarters; the thesis is relative rerating toward higher-margin recurring revenue while the market punishes peers exposed to wage pressure.
• If CERT rallies sharply on announcement, consider selling upside calls against a core long; the near-term risk is a classic ‘sell-the-news’ move once investors focus on the revenue step-down and the 2026 guidance reset.
• Small tactical long PWP only as a short-duration event trade into M&A revenue recognition; keep size modest because the fee contribution is likely immaterial versus the broader cycle, so the risk/reward is more about sentiment than fundamentals.
• Avoid chasing BCS; the article provides no direct economic linkage, and any read-through is too indirect to justify capital at current information density.